Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to asses...

Full description

Bibliographic Details
Main Authors: Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti Rannikko, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
oncolytic virus
adenovirus
checkpoint inhibitors
immunotherapy
tumor microenvironment
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1761229

Internet

http://dx.doi.org/10.1080/2162402X.2020.1761229

Similar Items